Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Next Previous
X
Search
Trial Profile

Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OpACIN-neo; PRADO

    • Most Recent Events

    • 24 Oct 2023 Results (n=86) assessing 6-yr event free survival rate in melanoma patients treated with ipilimumab plus nivolumab were presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Results assessing association between baseline biomarkers and 3-year survival, presented at the 48th European Society for Medical Oncology Congress
    • 03 Sep 2023 This Trial has been Discontinued in Austria according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top